drugset / Trial / NCT05636787
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
Timeline
- Start
- 2023-06-06
- Primary completion
- 2028-01
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 70 mg/m2 | — |
| Subject | Melphalan | Small molecule | 100 mg/m2 | — |
| Subject | Treosulfan | Small molecule | 14 mg/m2 | Intravenous |